Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab-Reference-Cited by-同舟云学术

Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab

Published:2018-02-16 Issue:4 Volume:19 Page:328-334
ISSN:1538-4047
Container-title:Cancer Biology & Therapy
language:en
Short-container-title:Cancer Biology & Therapy

Author:

Pizzuti Laura¹,Sergi Domenico¹,Sperduti Isabella²,Lauro Luigi Di¹,Mazzotta Marco³,Botti Claudio⁴,Izzo Fiorentino¹,Marchetti Luca⁵,Tomao Silverio⁶,Marchetti Paolo³,Natoli Clara⁷,Grassadonia Antonino⁷,Gamucci Teresa⁸,Mentuccia Lucia⁸,Magnolfi Emanuela⁸,Vaccaro Angela⁸,Cassano Alessandra⁹,Rossi Ernesto⁹,Botticelli Andrea³,Sini Valentina³¹⁰,Sarobba Maria G¹¹,Fabbri Maria Agnese¹²,Moscetti Luca¹³,Astone Antonio⁵⁹,Michelotti Andrea¹⁴,De Angelis Claudia¹⁴,Bertolini Ilaria¹⁴,Angelini Francesco¹⁵,Ciliberto Gennaro¹⁶,Maugeri-Saccà Marcello¹¹⁶,Giordano Antonio¹⁷,Barba Maddalena¹¹⁶,Vici Patrizia¹

Affiliation:

1. Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy

2. Biostatistics Unit and Clinical Trial Center, IRCCS Regina Elena National Cancer Institute, Rome, Italy

3. Medical Oncology Unit, Policlinico Sant'Andrea, Rome, Italy

4. Department of Surgery, IRCCS Regina Elena National Cancer Institute, Rome, Italy

5. Division of Medical Oncology, Villa San Pietro Hospital, Rome, Italy

6. Department of Medical-Surgical Sciences and Biotechnologies, La “Sapienza” University of Rome, Italy

7. Department of Medical, Oral and Biotechnological Sciences and CeSI-MeT, G. D'Annunzio University, Chieti, Italy

8. Medical Oncology Unit, ASL Frosinone, Frosinone, Italy

9. Department of Medical Oncology, Catholic University of Sacred Heart, Rome, Italy

10. Oncology Unit, ASL Roma 1, Santo Spirito Hospital, Rome, Italy

11. Medical Oncology Unit, ASL Nuoro, Nuoro, Italy

12. Division of Oncology, Complesso Ospedaliero Belcolle, AUSL Viterbo, Viterbo, Italy

13. Division of Medical Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy

14. Oncology Unit I, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy

15. Medical Oncology Unit, Regina Apostolorum Hospital, Albano, Rome, Italy

16. Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy

17. Sbarro Institute for Cancer Research and Molecular Medicine e del Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, USA

Funder

Originates From Spontaneous

Publisher

Informa UK Limited

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/15384047.2017.1416938

Reference22 articles.

1. Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer

2. Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

3. RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer